-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, the World Health Organization (WHO) announced that it has listed the new coronavirus mutant strain B.
1.
617 originally discovered in India as a variant of concern (VOC).
The listing of B.
1.
617 as a VOC means that the WHO believes that this mutant strain may be stronger than the wild-type new coronavirus in terms of transmission, pathogenicity, or immune escape ability, and it deserves attention at the global level.
So how strong is its communication ability? Can existing vaccines still provide protection? Today, "Nature" magazine also specially wrote an article listing the latest research results for B.
1.
617.
WuXi AppTec's content team will combine public information to discuss the answers to these questions with readers.
The evolution of the B.
1.
617 virus strain The concern about the B.
1.
617 virus strain is that it carries mutations in the S gene encoding the spike protein of the new coronavirus that may affect the ability of the virus to spread and evade the ability to recognize neutralizing antibodies.
Among them, previous experimental results show that L452R may improve the virus's ability to spread, while E484Q may improve the virus's immune escape ability.
Further analysis of B.
1.
617 found that it can be divided into 3 different sub-strains, namely B.
1.
617.
1, B.
1.
617.
2 and B.
1.
617.
3.
The gene mutations carried by these three different substrains are also slightly different.
It is worth mentioning that B.
1.
617.
2 does not carry the E484Q mutation, but it carries a T478K mutation that is not found in the other two substrains.
▲How about the neutralizing ability of the sera from vaccine vaccinators and COVID-19 patients who have recovered from COVID-19 with the important gene mutations carried by the various new coronavirus mutant virus strains that are currently receiving attention (graphic by WuXi AppTec's content team) against B.
1.
617? Whether the vaccine can protect B.
1.
617 may be one of the issues that people are most concerned about. Previously, researchers from India’s Bharat Biotech and the Indian Council of Medical Research-National Institute of Virology (ICMR) published a study on the preprint website bioRxiv, which showed the willingness to vaccinate the inactivated new crown vaccine COVAXIN produced in India Among the patients, although the neutralizing ability of serum to B.
1.
617 decreased compared with the wild type, the geometric mean titer (GMT) decreased by 1.
95 times.
These data show that although B.
1.
617 has a certain immune escape ability, existing vaccines may still have a protective effect on it.
Recently, a joint team in the United States published on bioRxiv a study on the neutralizing ability of B.
1.
617.
1 in sera from patients recovered from COVID-19 and two different mRNA new crown vaccine inoculators.
The results of the experiment found that, on average, the neutralizing ability of the serum of recovered patients and vaccinators to B.
1.
617.
1 was 6.
8 times lower than that of the wild-type virus.
However, 79% (19/24) of the recovered sera and all vaccinated sera were still able to neutralize the B.
1.
617.
1 mutant.
The researchers said that this means that the immunity brought by these two mRNA vaccines is still likely to have a protective effect on the B.
1.
617.
1 mutant.
▲Comparison of the neutralization ability between the serum of recovered patients and the serum of people inoculated with mRNA vaccination against wild-type new coronavirus (WA1) and B.
1.
617 (picture source: reference [6]) An article published by "Nature" stated that because the vaccine can stimulate the human body A large number of antibodies are produced, so the reduction of neutralizing antibody titer does not necessarily significantly affect the protective ability of the vaccine.
Previous studies on the B.
1.
351 mutant also showed that although it can cause a significant reduction in the neutralizing ability of neutralizing antibodies, in clinical trials, there are still a variety of vaccines that can have a high degree of protection against it, especially in prevention For serious diseases. Transmission ability of B.
1.
617 virus strain There are many reasons for the rapid increase in the number of new coronavirus cases in India.
In addition to the impact of the new coronavirus mutation, in previous reports published in Nature, industry experts also pointed out that the vaccination rate of the Indian population is low.
The opening of large-scale events, leading to a substantial increase in people's gathering and circulation is also an important reason for the surge in cases.
However, in countries other than India, the transmission ability of the B.
1.
617 mutant has also aroused the vigilance of local governments.
On May 7, the Public Health England (PHE) announced that B.
1.
617.
2 was listed as a VOC.
The announcement issued by PHE stated that the reason for listing B.
1.
617.
2 as a VOC is that there is evidence that its transmission capacity is greater than that of the wild-type new coronavirus, at least the same as the B.
1.
1.
7 virus strain originally discovered in the United Kingdom.
From the perspective of gene mutation, we already know that B.
1.
617.
2 may carry mutations that are more conducive to the spread of the virus.
Other evidence supporting this decision of PHE includes a model analysis of the growth of B.
1.
617.
2 cases showing that it can compete with the B.
1.
1.
7 strain in the UK population and has a transmission capacity at least equivalent to that of B.
1.
1.
7.
Dr.
Maria Van Kerkhove, WHO's technical lead (technical lead) for COVID-19, said at a press conference that the current preliminary research shows that B.
1.
617 has a stronger transmission capacity than the wild-type new coronavirus, but we still need more gene sequencing.
Data, obtain more information related to this mutant strain and its substrains, and further measure its impact on the health of the global population. Reference: [1] Coronavirus variants are spreading in India — what scientists know so far.
Retrieved May 11, 2021, from WHO will B.
1.
617, which was first discovered in India in December last year, is listed as a variant of the global concern for the new crown.
Retrieved May 11, 2021, from https://cn.
reuters.
com/article/who-india-health-coronavirus-0510-tues- idCNKBS2CS02A[3] Ferreira et al.
, (2021).
SARS-CoV-2 B.
1.
617 emergence and sensitivity to vaccine-elicited antibodies.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
08.
443253[4] Hoffmann et al.
, (2021).
SARS-CoV-2 variant B.
1.
617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
04.
442663[5] SARS-CoV -2 variants of concern and variants under investigation in England.
Retrieved May 11, 2021, from https://assets.
publishing.
service.
gov.
uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.
pdf[6] Edara et al.
, (2021).
Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.
1.
617.
1 variant.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
09.
443299.
Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
1.
617 originally discovered in India as a variant of concern (VOC).
The listing of B.
1.
617 as a VOC means that the WHO believes that this mutant strain may be stronger than the wild-type new coronavirus in terms of transmission, pathogenicity, or immune escape ability, and it deserves attention at the global level.
So how strong is its communication ability? Can existing vaccines still provide protection? Today, "Nature" magazine also specially wrote an article listing the latest research results for B.
1.
617.
WuXi AppTec's content team will combine public information to discuss the answers to these questions with readers.
The evolution of the B.
1.
617 virus strain The concern about the B.
1.
617 virus strain is that it carries mutations in the S gene encoding the spike protein of the new coronavirus that may affect the ability of the virus to spread and evade the ability to recognize neutralizing antibodies.
Among them, previous experimental results show that L452R may improve the virus's ability to spread, while E484Q may improve the virus's immune escape ability.
Further analysis of B.
1.
617 found that it can be divided into 3 different sub-strains, namely B.
1.
617.
1, B.
1.
617.
2 and B.
1.
617.
3.
The gene mutations carried by these three different substrains are also slightly different.
It is worth mentioning that B.
1.
617.
2 does not carry the E484Q mutation, but it carries a T478K mutation that is not found in the other two substrains.
▲How about the neutralizing ability of the sera from vaccine vaccinators and COVID-19 patients who have recovered from COVID-19 with the important gene mutations carried by the various new coronavirus mutant virus strains that are currently receiving attention (graphic by WuXi AppTec's content team) against B.
1.
617? Whether the vaccine can protect B.
1.
617 may be one of the issues that people are most concerned about. Previously, researchers from India’s Bharat Biotech and the Indian Council of Medical Research-National Institute of Virology (ICMR) published a study on the preprint website bioRxiv, which showed the willingness to vaccinate the inactivated new crown vaccine COVAXIN produced in India Among the patients, although the neutralizing ability of serum to B.
1.
617 decreased compared with the wild type, the geometric mean titer (GMT) decreased by 1.
95 times.
These data show that although B.
1.
617 has a certain immune escape ability, existing vaccines may still have a protective effect on it.
Recently, a joint team in the United States published on bioRxiv a study on the neutralizing ability of B.
1.
617.
1 in sera from patients recovered from COVID-19 and two different mRNA new crown vaccine inoculators.
The results of the experiment found that, on average, the neutralizing ability of the serum of recovered patients and vaccinators to B.
1.
617.
1 was 6.
8 times lower than that of the wild-type virus.
However, 79% (19/24) of the recovered sera and all vaccinated sera were still able to neutralize the B.
1.
617.
1 mutant.
The researchers said that this means that the immunity brought by these two mRNA vaccines is still likely to have a protective effect on the B.
1.
617.
1 mutant.
▲Comparison of the neutralization ability between the serum of recovered patients and the serum of people inoculated with mRNA vaccination against wild-type new coronavirus (WA1) and B.
1.
617 (picture source: reference [6]) An article published by "Nature" stated that because the vaccine can stimulate the human body A large number of antibodies are produced, so the reduction of neutralizing antibody titer does not necessarily significantly affect the protective ability of the vaccine.
Previous studies on the B.
1.
351 mutant also showed that although it can cause a significant reduction in the neutralizing ability of neutralizing antibodies, in clinical trials, there are still a variety of vaccines that can have a high degree of protection against it, especially in prevention For serious diseases. Transmission ability of B.
1.
617 virus strain There are many reasons for the rapid increase in the number of new coronavirus cases in India.
In addition to the impact of the new coronavirus mutation, in previous reports published in Nature, industry experts also pointed out that the vaccination rate of the Indian population is low.
The opening of large-scale events, leading to a substantial increase in people's gathering and circulation is also an important reason for the surge in cases.
However, in countries other than India, the transmission ability of the B.
1.
617 mutant has also aroused the vigilance of local governments.
On May 7, the Public Health England (PHE) announced that B.
1.
617.
2 was listed as a VOC.
The announcement issued by PHE stated that the reason for listing B.
1.
617.
2 as a VOC is that there is evidence that its transmission capacity is greater than that of the wild-type new coronavirus, at least the same as the B.
1.
1.
7 virus strain originally discovered in the United Kingdom.
From the perspective of gene mutation, we already know that B.
1.
617.
2 may carry mutations that are more conducive to the spread of the virus.
Other evidence supporting this decision of PHE includes a model analysis of the growth of B.
1.
617.
2 cases showing that it can compete with the B.
1.
1.
7 strain in the UK population and has a transmission capacity at least equivalent to that of B.
1.
1.
7.
Dr.
Maria Van Kerkhove, WHO's technical lead (technical lead) for COVID-19, said at a press conference that the current preliminary research shows that B.
1.
617 has a stronger transmission capacity than the wild-type new coronavirus, but we still need more gene sequencing.
Data, obtain more information related to this mutant strain and its substrains, and further measure its impact on the health of the global population. Reference: [1] Coronavirus variants are spreading in India — what scientists know so far.
Retrieved May 11, 2021, from WHO will B.
1.
617, which was first discovered in India in December last year, is listed as a variant of the global concern for the new crown.
Retrieved May 11, 2021, from https://cn.
reuters.
com/article/who-india-health-coronavirus-0510-tues- idCNKBS2CS02A[3] Ferreira et al.
, (2021).
SARS-CoV-2 B.
1.
617 emergence and sensitivity to vaccine-elicited antibodies.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
08.
443253[4] Hoffmann et al.
, (2021).
SARS-CoV-2 variant B.
1.
617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
04.
442663[5] SARS-CoV -2 variants of concern and variants under investigation in England.
Retrieved May 11, 2021, from https://assets.
publishing.
service.
gov.
uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.
pdf[6] Edara et al.
, (2021).
Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.
1.
617.
1 variant.
bioRxiv, https://doi.
org/10.
1101/2021.
05.
09.
443299.
Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
